What did J&J’s Spravato FDA approval mean?
Quick answer: The FDA’s March 2019 approval of Spravato (esketamine), developed by Johnson & Johnson, was the first truly novel mechanism for depression in decades — it acts on the brain’s glutamate/NMDA system, not the serotonin pathway used by SSRIs.[1] Spravato is now FDA-approved for two indications: treatment-resistant depression and major depressive disorder with acute suicidal ideation.[2,3] It is administered as a nasal spray under medical supervision at REMS-certified clinics, and is covered by Medicare and most major commercial insurance — distinguishing it from off-label IV ketamine.
For clinicians: If you’re considering referring a patient for ketamine therapy or Spravato (esketamine), submit a referral here →
What Should Psychiatrists and NPs Know About Spravato (Esketamine)?
Key clinical facts for referring providers and prescribing clinicians considering esketamine for treatment-resistant depression:
- FDA-approved indications: Spravato (esketamine) is FDA-approved for two indications — treatment-resistant depression (TRD, defined as failure of two adequate antidepressant trials in the current episode) and major depressive disorder with acute suicidal ideation or behavior (MDSI). It is the first FDA-approved depression treatment in decades to act on the glutamate/NMDA system rather than serotonin.
- REMS monitoring: Spravato is dispensed and administered only at REMS-certified treatment centers. Each session requires a post-dose monitoring period of two hours or more for sedation and dissociation, and patients cannot drive after a session.[2] Clinicians refer; the certified center handles dispensing and monitoring.
- Insurance coverage: Spravato is covered by Medicare and most major commercial insurers (including Aetna, BCBS, Cigna, UnitedHealthcare, and others), distinguishing it from off-label IV or IM ketamine, which is rarely covered.[4]
- Eligibility screening: Suitable candidates are typically adults with TRD or MDSI, no active psychosis, controlled blood pressure, no recent substance use disorder, and no contraindicated medications. Pregnancy is a contraindication.
- Coordination with referrers: Most certified centers (including Lumin Health) coordinate dosing, monitoring, and clinical updates back to the referring psychiatrist, NP, PCP, or therapist — so the patient’s primary clinician stays in the loop without taking on direct dosing or monitoring responsibilities.
- Distinction from off-label ketamine: Generic IV/IM ketamine for mood disorders is off-label, racemic (both enantiomers), variably dosed, and rarely insurance-covered. Spravato is FDA-approved, esketamine-only, fixed-dose (56 or 84 mg), insurance-covered, and REMS-monitored.
Referring a patient? Submit a referral → or see the full clinician resource hub.
Sources: FDA Approval Letter (NDA 211243), FDA Spravato REMS Program, NIMH on depression and esketamine.
Understanding the Landmark Johnson & Johnson Spravato FDA Approval
The Johnson & Johnson Spravato FDA approval marked a pivotal moment for mental healthcare, offering the first truly novel mechanism for depression treatment in decades. This approval provides a rigorously tested and regulated option for adults with treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).
The Clinical Distinction: Spravato vs. Off-Label Ketamine Therapy
While often discussed together, it is crucial to understand the distinct clinical and regulatory differences between Spravato and IV ketamine. The FDA approval for Johnson & Johnson's product applies only to Spravato (which is the brand name for esketamine), a specific component of the ketamine molecule, administered as a nasal spray.
Other forms of ketamine administration, while backed by significant evidence, are considered "off-label." At Lumin Health, our psychiatrist-led team is deeply experienced in guiding patients through the nuances of these options to determine the most appropriate path forward.
How Esketamine Works: Unsticking Rigid Brain Patterns
Chronic depression can cause the brain's communication pathways to become rigid and stuck. Instead of just modulating serotonin, Spravato targets the NMDA receptor, leading to a surge in a neurotransmitter called glutamate. This surge is believed to trigger a cascade of events that promotes neuroplasticity – the brain's ability to form new connections. Essentially, this form of ketamine for depression can create a window of time where the brain is more flexible and receptive to forming new, healthier thought patterns. A study published in the American Journal of Psychiatry highlighted this rapid antidepressant effect as a key benefit of the treatment.[2] It can contribute to how the medication helps a person feel unstuck.
Dr. Ben Yudkoff, Chief Medical Officer at Lumin Health, notes, "We often tell patients that their brain isn't broken – it may just be stuck in a deeply worn groove. The goal of treatments like Spravato is not to erase their experience, but to provide the biological opportunity to carve new, more adaptive pathways out of that groove. It's about creating a receptive state for change."
The Patient Experience at a Certified Treatment Center
The regulations surrounding the Spravato FDA approval ensure a highly controlled and safe patient experience. It is not a prescription you can take home. The entire process occurs at a certified practice like Lumin Health under the guidance of our medical team.
Navigating Safety, Efficacy, and Real-World Outcomes
The approval of Spravato was based on a robust body of clinical trials demonstrating its efficacy for patients who had not found relief from other treatments. The data, including findings published in leading journals like Neuropsychiatric Disease and Treatment, showed a statistically significant reduction in depressive symptoms for the Spravato group compared to placebo. Safety is the cornerstone of this therapy. The requirement for administration in a certified medical setting is specifically designed to manage potential side effects, such as a temporary increase in blood pressure or feelings of dissociation.
A Path Forward Towards Relief
Navigating advanced treatments for depression can feel overwhelming. The Johnson & Johnson Spravato FDA approval provides a vital, evidence-based option for many who felt they had run out of hope. At Lumin Health, a psychiatrist-led practice in Massachusetts, we are committed to providing personalized, attentive care that honors your unique journey.
We hope this guide serves as a valuable educational resource for individuals and families everywhere. If you are exploring treatment, our focus is on providing a safe, medically rigorous environment for your care. We would be grateful to walk with you towards relief.
References
- Cheng YJ, Lin CH, Lane HY. Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology. 2023;223:109351. PubMed
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. PubMed
- Fu DJ, Ionescu DF, Li X, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry. 2020;81(3). PubMed
- Ross EL, Soeteman DI. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatr Serv. 2020;71(10):988-997. PubMed
Take the first step today.
If you or a loved one in Massachusetts and the greater Washington DC/Maryland area is struggling with depression or anxiety, Lumin Health's team of experts is ready to help. Book a free 20-minute consultation to learn if ketamine therapy could be the breakthrough you've been looking for.
Available in Massachusetts and the greater Washington DC/Maryland area.
Frequently Asked Questions
Who makes Spravato?
Esketamine (Spravato) is manufactured by Janssen, a Johnson & Johnson company, and it was approved by the FDA in March 2019. It's the first treatment in decades to work on the brain's glutamate system rather than the serotonin pathway used by SSRIs.
Why is Spravato FDA-approved but ketamine is not?
Spravato went through the FDA's full clinical trial and approval process specifically for treatment-resistant depression and major depression with suicidal thoughts. Ketamine for depression uses a related molecule off-label, meaning it has not gone through that depression-specific approval process, even though it is supported by a body of clinical research.
What is Spravato FDA-approved to treat?
Esketamine (Spravato) is FDA-approved for adults with treatment-resistant depression, and for major depressive disorder with acute suicidal thoughts or behavior when used together with an oral antidepressant.
Is Spravato covered by insurance?
Spravato is covered by Medicare and most major commercial insurers, which sets it apart from off-label IV or IM ketamine, which is rarely covered. Check with your insurer or use our eligibility form at lumin.health/insurance-we-accept to confirm your specific plan.
How is Spravato different from the ketamine I may have heard about elsewhere?
Esketamine is one specific, active component of the ketamine molecule, delivered in a low, predictable dose in a controlled medical setting. That is very different from illicit or recreational use, where doses and purity are unknown and there is no medical supervision.
